Status:
UNKNOWN
Is Recombinant Growth Hormone Therapy Associated With Increased Intraoccular Pressure?
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Growth Hormone Treatment
Glaucoma
Eligibility:
All Genders
6-18 years
Brief Summary
Recombinant growth hormone is a common therapy in the pediatric population. A number of associated side effects have been described. Several years ago, a case report was published concerning a child t...
Eligibility Criteria
Inclusion
- Age 6-18 years
- treatment with recombinant growth hormone
Exclusion
- Underlying Chronic diseases
- Family history of eye diseases
- elevated occular pressure prior to starting treatment
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2010
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00867971
Start Date
February 1 2009
End Date
October 1 2010
Last Update
March 24 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assaf harofeh medical center
Ẕerifin, Israel